Cefiderocol + Standard of Care Antibiotic
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Pneumonia
Conditions
Bacterial Pneumonia
Trial Timeline
Feb 20, 2019 → Oct 15, 2019
NCT ID
NCT03862040About Cefiderocol + Standard of Care Antibiotic
Cefiderocol + Standard of Care Antibiotic is a phase 1 stage product being developed by Shionogi for Bacterial Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03862040. Target conditions include Bacterial Pneumonia.
What happened to similar drugs?
5 of 20 similar drugs in Bacterial Pneumonia were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03862040 | Phase 1 | Terminated |
Competing Products
20 competing products in Bacterial Pneumonia